| Ticker |
NMRA
|
| CIK | 0001885522 |
| SIC | 2836 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Biological Products, Except Diagnostic Substances |
| Address | 490 ARSENAL WAY, SUITE 200, WATERTOWN, MA, 02472 |
| Website | neumoratx.com |
| Phone | (857) 760-0900 |
| CEO | Henry O. Gosebruch |
| Employees | N/A |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform RatingNeumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the 11 Best New Penny Stocks to Buy Right Now. On July 16, Mizuho increased its price target for Neumora Therapeutics, Inc. (NASDAQ:NMRA) from $4 to $5 and kept an “Outperform” rating. This decision came after Neumora Therapeutics, Inc. (NASDAQ:NMRA) introduced NMRA-861, which is a strong and selective […] Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform RatingNeumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the hot penny stocks to invest in now. On July 16, Mizuho analyst Graig Suvannavejh raised the firm’s price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA) to $5 from $4, maintaining an Outperform rating on the shares. The rating update came after the introduction of NMRA-861 on July 9, when […] Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced the initiation of a Phase 1 sin Aldeyra Therapeutics Leads The Pack Among 3 Promising Penny StocksThe market has stayed flat over the past week, but it is up 13% over the past year, with earnings forecasted to grow by 15% annually. In such a setting, investors often look for stocks that combine value and growth potential, particularly those that may not be on everyone's radar. Penny stocks—though an outdated term—still offer intriguing opportunities when backed by strong financials and fundamentals, making them worth considering for investors seeking promising under-the-radar companies. |
